Nanomedicine from amphiphilized prodrugs: Concept and clinical translation

Nanomedicines generally consisting of carrier materials with small fractions of active pharmaceutical ingredients (API) have long been used to improve the pharmacokinetics and biodistributions, augment the therapeutic efficacies and mitigate the side effects. Amphiphilizing hydrophobic/hydrophilic drugs to prodrugs capable of self-assembly into well-defined nanostructures has emerged as a facile approach to fabricating nanomedicines because this amphiphilized prodrug (APD) strategy presents many advantages, including minimized use of inert carrier materials, well-characterized prodrug structures, fixed and high drug loading contents, 100% loading efficiency, and burst-free but controlled drug release. This review comprehensively summarizes recent advances in APDs and their nanomedicines, from the rationale and the stimuli-responsive linker chemistry for on-demand drug release to their progress to the clinics, clinical performance of APDs, as well as the challenges and perspective on future development. (c) 2021 Elsevier B.V. All rights reserved.

Automated summary

Nanomedicines, composed of carrier materials and small amounts of active pharmaceutical ingredients, have been widely used to improve therapeutic effects and reduce side effects. Converting hydrophobic/hydrophilic drugs into prodrugs capable of self-assembly into nanostructures offers many advantages, including high drug loading efficiency and controlled release. This review comprehensively summarizes recent advances in APDs and their nanomedicines, as well as the challenges and future prospects.